Drugs Brain and Behavior (DDP)

The University of Chicago

Status and phase: Completed; Early Phase 1

Conditions: Stimulant Use

Treatments: Drug: Methamphetamine; Drug: placebo oral tablet

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT04642820

R01DA002812 (U.S. NIH Grant/Contract)

IRB20-0364

Details and patient eligibility

About

In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.

Enrollment: 138 patients

Sex: All

Ages: 18 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• BMI between 19 and 26
• Right Handed
• Less than 4 alcohol or caffeinated beverages a day.

Exclusion criteria

• High blood pressure
• Any medical condition requiring regular medication
• Individuals with a current (within the last year) DSM-IV Axis 1 diagnosis
• Individuals with a history of dependence on stimulant drugs
• Women who are pregnant or trying to become pregnant.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

138 participants in 2 patient groups

Placebo Then Methamphetamine

Experimental group

Description:

Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.

Treatment:

Drug: placebo oral tablet

Drug: Methamphetamine

MethamphetamineThen Placebo

Experimental group

Description:

Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.

Treatment:

Drug: placebo oral tablet

Drug: Methamphetamine